Skip to main content

Advertisement

SpringerLink
Log in

Evaluating distant metastases in breast cancer: from biology to outcomes

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

There is an urgent need to understand distant metastases in breast cancer as they are the most lethal form of recurrence and a major cause of mortality in patients. Some predictors for distant metastases, including nodal status, tumor grade, and hormonal status, are useful in identifying patients at increased risk for distant metastases. Adjuvant endocrine therapy has been the treatment of choice for postmenopausal women with hormone-sensitive breast cancer, and some therapies have shown significant reductions in the risk of distant metastases. Skeletal metastases in breast cancer are treated with bisphosphonates with a certain level of success. With more new agents undergoing clinical trials, a thorough review of the specific and long-term safety of these agents is essential, as is a better understanding of the deterioration in the quality of life and cost concerns of patients who develop distant metastases. Gene-expression profiling is a new entrant in the field of distant metastases diagnosis, which is largely successful in defining gene signatures that predict the development of distant metastases. This review will discuss the biology and the impact of distant metastases on outcomes for patients with breast cancer; it also encompasses the current status, emerging focus, and future perspectives in treatment of skeletal metastases in patients with breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kryj, M., Maciejewski, B., Withers, H. R., & Taylor, J. M. (1997). Incidence and kinetics of distant metastases in patients with operable breast cancer. Neoplasma, 44, 3–1.

    PubMed  CAS  Google Scholar 

  2. Hanahan, & D., Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100, 57–0.

    Article  PubMed  CAS  Google Scholar 

  3. Parker, B., & Sukumar, S. (2003). Distant metastasis in breast cancer: molecular mechanisms and therapeutic targets. Cancer Biology and Therapy, 2, 14–1.

    PubMed  Google Scholar 

  4. Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002). Dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer, 2, 563–72.

    Article  PubMed  CAS  Google Scholar 

  5. Weigelt, B., Peterse, J., & van’t Veer, L. J. (2005). Breast cancer metastasis: Markers and models. Nature Reviews Cancer, 5, 591–02.

    Article  PubMed  CAS  Google Scholar 

  6. Hayes, D. F., & Kaplan, W. (1996). Evaluation of patients after primary therapy. In J. R. Harris, M. E. Lippman, M. Morrow (eds), Diseases of the breast (pp. 629–47). Philadelphia: Lippincott’Raven.

    Google Scholar 

  7. Chelouche, L. D., & Price, J. E. (2002). Therapeutic intervention with breast cancer metastasis. Critical Reviews in Eukaryotic Gene Expression, 12, 137–50.

    Article  Google Scholar 

  8. Bogenrieder, T., & Herlyn, M. (2003). Axis of evil: Molecular mechanisms of cancer metastasis. Oncogene, 22, 6524–536.

    Article  PubMed  CAS  Google Scholar 

  9. Weigelt, B., Glas, A. M., Wessels, L. F., Witteveen, A. T., Peterse, J. L., & van’t Veer, L. J. (2003). Gene expression profiles of primary breast tumors maintained in distant metastases. Proceedings of the National Academy of Sciences of the United States of America, 100, 15901–5905.

    Article  PubMed  CAS  Google Scholar 

  10. Patey, D. H., & Dyson, W. H. (1948). The prognosis of carcinoma of the breast in relation to the type of operation performed. British Journal of Cancer, 2, 7–3.

    PubMed  CAS  Google Scholar 

  11. Lamerato, L., Havstad, S., Gandhi, S., Jones, D., & Chlebowski, R. (2005). Breast cancer recurrence and related mortality in US patients with early breast cancer. Journal of Clinical Oncology, 25(Suppl 16), 62s, Abstract 738.

    Google Scholar 

  12. Ruoslahti, E. (1996). How cancer spreads? Scientific American, 275, 72–7.

    Article  PubMed  CAS  Google Scholar 

  13. Yokota, J. (2000). Tumor progression and metastasis. Carcinogenesis, 21, 497–03.

    Article  PubMed  CAS  Google Scholar 

  14. Betapudi, V., Licate, L. S., & Egelhoff, T. T. (2006). Distinct roles of nonmuscle myosin II isoforms in the regulation of MDA-MB-231 breast cancer cell spreading and migration. Cancer Research, 66, 4725–733.

    Article  PubMed  CAS  Google Scholar 

  15. Fidler, I. J. (1991). Cancer metastasis. British Medical Bulletin, 47, 157–77.

    PubMed  CAS  Google Scholar 

  16. Schmidt-Kittler, O., Ragg, T., Daskalakis, A., Granzow, M., Ahr, A., Blankenstein, T. J. F., et al. (2003). From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 100, 7737–742.

    Article  PubMed  CAS  Google Scholar 

  17. Tong, D., Czerwenka, K., Heinze, G., Ryffel, M., Schuster, E., Witt, A., et al. (2006). Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer. Clinical Cancer Research, 12, 2442–448.

    Article  PubMed  CAS  Google Scholar 

  18. Elder, E. E., Kennedy, C. W., Gluch, L., Carmalt, H. L., Janu, N. C., Joseph, M. G., et al. (2006). Patterns of breast cancer relapse. European Journal of Surgical Oncology, 20, 1–.

    Google Scholar 

  19. Solomayer, E. F., Diel, I. J., Meyberg, G. C., Gollan, C., Bastert, G. (2000). Metastatic breast cancer: Clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Research and Treatment, 59, 271–78.

    Article  PubMed  CAS  Google Scholar 

  20. Gupta, G. P., Minn, A. J., Kang, Y., Siegel, P. M., Serganova, I., Cordon-Cardo, C., et al. (2005). Identifying site-specific metastasis genes and functions. Cold Spring Harbor Symposia on Quantitative Biology, 70, 149–58.

    Article  PubMed  CAS  Google Scholar 

  21. Cairns, R. A., Khokha, R., & Hill, R. P. (2003). Molecular mechanisms of tumor invasion and metastasis: An integrated view. Current Molecular Medicine, 3, 659–71.

    Article  PubMed  CAS  Google Scholar 

  22. Rakha, E. A., Abd El Rehim, D., Pinder, S. E., Lewis, S. A., & Ellis, I. O. (2005). E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology, 46, 685–93.

    Article  PubMed  CAS  Google Scholar 

  23. Sloan, E. K,, Pouliot, N., Stanley, K. L., Chia, J., Moseley, J. M., Hards, D. K., et al. (2006). Tumor-specific expression of ávâ3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Research, 8, R20.

    Article  PubMed  CAS  Google Scholar 

  24. Allan, A. L., George, R., Vantyghem, S. A., Lee, M. W., Hodgoson, N. C., Engel, J., et al. (2006). Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. American Journal of Pathology, 169, 233–46.

    Article  PubMed  CAS  Google Scholar 

  25. Jezierska, A., Olszewski, W. P., Pietruszkiewicz, J., Olszewski, W., Matysiak, W., & Motyl, T. (2006). Activated leukocyte cell adhesion molecule (ALCAM) is associated with suppression of breast cancer cells invasion. Medical Science Monitor, 12, BR245–56.

    PubMed  CAS  Google Scholar 

  26. Tetu, B., Brisson, J., Wang, C. S., Lapointe, H., Beaudry, G., Blanchette, C., et al. (2006). The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Research, 8, R28.

    Article  PubMed  CAS  Google Scholar 

  27. Sang, Q. X. (1998). Complex role of matrix metalloproteinases in angiogenesis. Cell Research, 8, 171–77.

    PubMed  CAS  Google Scholar 

  28. Zucker, S., Lysik, R. M., Zarrabi, M. H., & Moll, U. (1993). Mr 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Research, 53, 140–46.

    PubMed  CAS  Google Scholar 

  29. Sommerfeldt, N., Beckhove, P., Ge, Y., Schutz, F., Choi, C., Bucur, M., et al. (2006). A new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes. Cancer Research, 66, 7716–723.

    Article  PubMed  CAS  Google Scholar 

  30. Wurtz, S. O., Schrohl, A. S., Sorensen, N. M., Lademann, U., Christensen, I. J., Mouridsen, H., et al. (2005). Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocrine-Related Cancer, 12, 215–27.

    Article  PubMed  CAS  Google Scholar 

  31. Mundy, G. R. (2002). Metastasis to bone: Causes, consequences and therapeutic opportunities. Nature Reviews Cancer, 2, 584–93.

    Article  PubMed  CAS  Google Scholar 

  32. Nishimura, R., Nagao, K., Miyayama, H., Matsuda, M., Baba, K., Yamashita, H., et al. (2003). Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53, and recurrence of breast cancer. Breast Cancer, 10, 120–28.

    Article  PubMed  Google Scholar 

  33. Kang, Y., He, W., Tulley, S., Gupta, G. P., Serganova, I., Chen, C.-R., et al. (2005). Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proceedings of the National Academy of Sciences of the United States of America, 102, 13909–3914. Erratum in: Proc Natl Acad Sci USA 103:8570, 2006

    Article  PubMed  CAS  Google Scholar 

  34. Rabbani, S. A. (2000). Molecular mechanism of action of parathyroid hormone related peptide in hypercalcemia of malignancy: therapeutic strategies (review). International Journal of Oncology, 16, 197–06.

    PubMed  CAS  Google Scholar 

  35. Wülfing, P., Borchard, J., Heidl, S., Zänker, K. S., Kiesel, L., & Brandt, B. (2005). Prognostic value of blood-borne epithelium-derived c-erbB2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients. Journal of Clinical Oncology, 25(Suppl 16), 874s, Abstract 9625.

    Google Scholar 

  36. Xue, C., Liang, F., Mahmood, R., Vuolo, M., Wyckoff, J., Qian, H., et al. (2006a). ErbB3-dependent motility and intravasation in breast cancer metastasis. Cancer Research, 66, 1418–426.

    Article  PubMed  CAS  Google Scholar 

  37. Xue, C., Wyckoff, J., Liang, F., Sidani, M., Violini, S., Tsai, K. L., et al. (2006b). Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Research, 66, 192–97. Erratum in: Cancer Res 66: 4547, 2006.

    Article  PubMed  CAS  Google Scholar 

  38. Lopez, T., & Hanahan, D. (2002). Elevated levels of the IGF-I receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorogenesis. Cancer Cell, 1, 339–53.

    Article  PubMed  CAS  Google Scholar 

  39. Pardali, K., & Moustakas, A. (2007). Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochimica et Biophysica Acta, 1775, 21–2.

    PubMed  CAS  Google Scholar 

  40. Schwertfeger, K. L., Xian, W., Kaplan, A. M., Burnett, S. H., Cohen, D. A., & Rosen, J. M. (2006). A critical role for the inflammatory response in a mouse model of preneoplastic progression. Cancer Research, 66, 5676–685.

    Article  PubMed  CAS  Google Scholar 

  41. Jorcyk, C. L., Holzer, R. G., & Ryan, R. E. (2006). Oncostatin M induces cell detachment and enhances the metastatic capacity of T-47D human breast carcinoma cells. Cytokine, 33, 323–36.

    Article  PubMed  CAS  Google Scholar 

  42. Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature, 410, 50–6.

    Article  PubMed  CAS  Google Scholar 

  43. Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438, 820–27.

    Article  PubMed  CAS  Google Scholar 

  44. Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhofer, N., Kong, C., Le, Q.-T., et al. (2006). Lysyl oxidase is essential for hypoxia-induced metastasis. Nature, 440, 1222–226.

    Article  PubMed  CAS  Google Scholar 

  45. Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., et al. (2005). Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. Journal of the National Cancer Institute, 97, 1262–271.

    Article  PubMed  CAS  Google Scholar 

  46. Chia, K. S., Du, W. B., Sankaranarayanan, R., Sankila, R., Wang, H., Lee, J., et al. (2004). Do younger female breast cancer patients have a poorer prognosis? Results from a population-based survival analysis. International Journal of Cancer, 108, 761–65.

    Article  CAS  Google Scholar 

  47. Holmgren, L., O’Reilly, M. S., & Folkman, J. (1995). Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Medicine, 1, 149–53.

    Article  PubMed  CAS  Google Scholar 

  48. Cianfrocca, M., & Goldstein, L. J. (2004). Prognostic and predictive factors in early-stage breast cancer. Oncologist, 9, 606–16.

    Article  PubMed  Google Scholar 

  49. Cobleigh, M. A., Tabesh, B., Bitterman, P., Baker, J., Cronin, M., Liu, M.-L., et al. (2005). Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clinical Cancer Research, 11, 8623–631.

    Article  PubMed  CAS  Google Scholar 

  50. Gonzalez-Angulo, A. M., McGuire, S. E., Buchholz, T. A., Tucker, S. L., Querer, H. M., Rouzier, R., et al. (2005). Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. Journal of Clinical Oncology, 23, 7098–104.

    Article  PubMed  Google Scholar 

  51. Komoike, Y., Akiyama, F., Iino, Y., Ikedo, T., Akashi-Tanaka, S., Ohsumi, S., et al. (2006). Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: Risk factors and impact on distant metastases. Cancer, 106, 35–1.

    Article  PubMed  Google Scholar 

  52. Bijker, N., Peterse, J. L., Duchateau, L., Julien, J.-P., Fentiman, I. S., Duval, C., et al. (2001). Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European organization for research and treatment of cancer trial 10853. Journal of Clinical Oncology, 19, 2263–271.

    PubMed  CAS  Google Scholar 

  53. Lawrence, G., Pritchard, M. G., Kearins, O., & Casey, M. (2005). An analysis of breast cancer recurrences for screen detected and symptomatic breast cancers diagnosed in the West Midlands in 1996 and 1997. Breast Cancer Research and Treatment, 94(Suppl 1), S211, Abstract 5019.

    Google Scholar 

  54. Thames, H. D., Buchholz, T. A., & Smith, C. D. (1999). Frequency of first metastatic events in breast cancer: Implications for sequencing of systemic and local-regional treatment. Journal of Clinical Oncology, 17, 2649–658.

    PubMed  CAS  Google Scholar 

  55. Diel, I. J., Kaufmann, M., Costa, S. D., Holle, R., von Minckwitz, G., Solomayer, E. F., et al. (1996). Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status. Journal of the National Cancer Institute, 88, 1652–658.

    Article  PubMed  CAS  Google Scholar 

  56. Schindlbeck, C., Jeschke, U., Schulze, S., Karsten, U., Janni, W., Rack, B., et al. (2007). Prognostic impact of Thomsen’Friedenreich tumor antigen and disseminated tumor cells in the bone marrow of breast cancer patients. Breast Cancer Research and Treatment, 101, 17–5.

    Article  PubMed  CAS  Google Scholar 

  57. Vogl, F. D., Braun, S., & Pantel, K. (2006). Prognostic value of bone marrow micrometastasis on disease outcome in 4703 breast cancer patients: Meta- and pooled analysis after 10 years of follow-up. European Journal of Cancer Supplement, 4, 109, Abstract 210.

    Article  Google Scholar 

  58. Goldstein, N. S., Vicini, F. A., Hunter, S., Odish, E., Forbes, S., Kraus, D., et al. (2005). Molecular clonality determination of ipsilateral recurrence of invasive breast carcinomas after breast-conserving therapy: Comparison with clinical and biologic factors. American Journal of Clinical Pathology, 123, 679–89.

    Article  PubMed  Google Scholar 

  59. Vicini, F. A., Kestin, L., Huang, R., & Martinez, A. (2003). Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy? Cancer, 97, 910–19.

    Article  PubMed  Google Scholar 

  60. Kamby, C., & Sengelov, L. (1997). Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer. A prospective study with more than 10 years of follow-up. Breast Cancer Research and Treatment, 45, 181–92.

    Article  PubMed  CAS  Google Scholar 

  61. Haylock, B. J., Coppin, C. M., Jackson, J., Basco, V. E., & Wilson, K. S. (2000). Locoregional first recurrence after mastectomy: Prospective cohort studies with and without immediate chemotherapy. International Journal of Radiation Oncology, Biology, Physics, 46, 355–62.

    Article  PubMed  CAS  Google Scholar 

  62. Doyle, T., Schultz, D. J., Peters, C., Harris, E., & Solin, L. J. (2001). Long-term results of local recurrence after breast conservation treatment for invasive breast cancer. International Journal of Radiation Oncology, Biology, Physics, 51, 74–0.

    PubMed  CAS  Google Scholar 

  63. Moran, M. &Haffty, B. S. (2002). Local’regional breast cancer recurrence: Prognostic groups based on patterns of failure. Breast Journal, 8, 81–7.

    Article  PubMed  Google Scholar 

  64. Veronesi, U., Marubini, E., Del Vecchio, M., Manzari, A., Andreola, S., Greco, M., et al. (1995). Local recurrences and distant metastases after conservative breast cancer treatments: Partly independent events. Journal of the National Cancer Institute, 87, 19–7.

    Article  PubMed  CAS  Google Scholar 

  65. Fowble, B. L. (1999). Ipsilateral breast tumor recurrence following breast-conserving surgery for early-stage invasive cancer. Acta Oncológica, 38(Suppl 13), 9–7.

    Article  PubMed  Google Scholar 

  66. Cowen, D., Jacquemier, J., Houvenaeghel, G., Viens, P., Puig, B., Bardou, V.-J., et al. (1998). Local and distant recurrence after conservative management of “very low risk–breast cancer are dependent events: A 10-year follow-up. International Journal of Radiation Oncology, Biology, Physics, 41, 801–07.

    PubMed  CAS  Google Scholar 

  67. Chlebowski, R. T., Aiello, E., & McTiernan, A. (2002). Weight loss in breast cancer patient management. Journal of Clinical Oncology, 20, 1128–143.

    Article  PubMed  Google Scholar 

  68. Ligibel, J. A., Chlebowski, R. T., & Goodwin, P. J. (2006). The effect of lifestyle factors on breast cancer prognosis. American Society of Clinical Oncology, 2006, 16–0 Education Book.

    Google Scholar 

  69. van de Vijver, M. J., He, Y. D., van’t Veer, L. J., Dai, H., Hart, A. A. M., Voskul, D. W., et al. (2002). A gene-expression signature as a predictor of survival in breast cancer. New England Journal of Medicine, 347, 1999–009.

    Article  PubMed  Google Scholar 

  70. van’t Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415, 530–36.

    Article  Google Scholar 

  71. Ahr, A., Karn, T., Solbach, C., Seiter, T., Strebhardt, K., Holtrich, U., et al. (2002). Identification of high risk breast-cancer patients by gene expression profiling. Lancet, 359, 131–32.

    Article  PubMed  Google Scholar 

  72. Wang, Y., Klijn, J. G., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., et al. (2005). Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet, 365, 671–79.

    PubMed  CAS  Google Scholar 

  73. Desmedt, C., Piette, F., Cardoso, F., Wang, Y., Loi, S., Lallemand, F., et al. (2006). TRANSBIG multi-centre independent validation of the Rotterdam 76-gene prognostic signature for patients with node-negative breast cancer. 5th European Breast Cancer Conference; March 21–5, 2006; Nice, France. Late-breaking abstract. Available at: http://www.fecs.be/emc.asp?pageId=611&Type=P.

  74. Lau, K. F., Wang, A., Chew, K., Dai, H., Hastie, T., Brandt, B., et al. (2006). An RT-PCR-based multi-gene prognostic signature predicts distant metastasis of node negative, ER positive breast cancer from FFPE sections. Journal of Clinical Oncology, 24, 18S, Abstract 506.

    Article  Google Scholar 

  75. Breast International Group (BIG) 1–8 Collaborative Group; Thurlimann, B., Keshaviah, A., Coates, A. S., Mouridsen, H., Mauriac, L., et al. (2005). A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New England Journal of Medicine, 353, 2747–757.

    Article  PubMed  Google Scholar 

  76. Martens, G. W. M. (2006). Gene expression profile associated with breast cancer metastasizing to bone. European Journal of Cancer Supplement, 4, 136, Abstract 302.

    Article  Google Scholar 

  77. Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., et al. (2005). Genes that mediate breast cancer metastasis to lung. Nature, 436, 518–24.

    Article  PubMed  CAS  Google Scholar 

  78. Landemaine, T., Jackson, A., Teti, A., Sierra, A., Garcia, T., Driouch, K., et al. (2006). Gene profiling analysis of tissue-specific metastases from human breast cancer. European Journal of Cancer. Supplement, 4, 139, Abstract 312.

    Article  Google Scholar 

  79. Karabali-Dalamaga, S., Souhami, R. L., O’Higgins, N. J., Soumilas, A., & Clark, C. G. (1978). Natural history and prognosis of recurrent breast cancer. British Medical Journal, 2, 730–33.

    Article  PubMed  CAS  Google Scholar 

  80. Lê, M. G., Arriagada, R., Spielmann, M., Guinebretière, J. M., & Rochard, F. (2002). Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer, 94, 2813–820.

    Article  PubMed  Google Scholar 

  81. Mansi, J. L., Gogas, H., Bliss, J. M., Gazet, J.-C., Berger, U., & Coombes, R. C. (1999). Outcome of primary-breast-cancer patients with micrometastases: A long-term follow-up study. Lancet, 354, 197–02.

    Article  PubMed  CAS  Google Scholar 

  82. Landys, K., Persson, S., Kovarik, J., Hultborn, & R., Holmberg, E. (1998). Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: Results of a 20-year median follow-up. Breast Cancer Research and Treatment, 49, 27–3.

    Article  PubMed  CAS  Google Scholar 

  83. Lamerato, L., Havstad, S., Gandhi, S., Jones, D., Nathanson, D. (2006). Economic burden associated with breast cancer recurrence: Findings from a retrospective analysis of health system data. Cancer, 106, 1875–882.

    Article  PubMed  Google Scholar 

  84. Northouse, L. L., Mood, D., Kershaw, T., Schafenacker, A., Mellon, S., Walker, J., et al. (2002). Quality of life of women with recurrent breast cancer and their family members. Journal of Clinical Oncology, 20, 4050–064.

    Article  PubMed  Google Scholar 

  85. Oh, S., Heflin, L., Meyerowitz, B. E., Desmond, K. A., Rowland, J. H., & Ganz, P. A. (2004). Quality of life of breast cancer survivors after a recurrence: A follow-up study. Breast Cancer Research Treatment, 87, 45–7.

    Article  Google Scholar 

  86. Dorval, M., Maunsell, E., Deschenes, L., Brisson, J., & Masse, B. (1998). Long-term quality of life after breast cancer: Comparison of 8-year survivors with population controls. Journal of Clinical Oncology, 16, 487–94.

    PubMed  CAS  Google Scholar 

  87. Sorensen, S. V., Brown, R., Benedict, A., Flood, E., & Revicki, D. (2004). Patient-rated utilities in postmenopausal early breast cancer (EBC): A cross-country comparison. Value Health, 7, 641–42.

    Google Scholar 

  88. Lindley, C., Vasa, S., Sawyer, W. T., & Winer, E. P. (1998). Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. Journal of Clinical Oncology, 16, 1380–387.

    PubMed  CAS  Google Scholar 

  89. Monteiro Grillo, I., Jorge, M., Marques Vidal, P., Ortiz, M., & Ravasco, P. (2005). The effect of locoregional recurrence on survival and distant metastasis after conservative treatment for invasive breast carcinoma. Clinical Oncology (R Coll Radiol), 17, 111–17.

    CAS  Google Scholar 

  90. Mikhitarian, K., Gillanders, W. E., Almeida, J. S., Martin, R. H., Varela, J. C., Metcalf, J. S., et al. (2005). An innovative microarray strategy identities informative molecular markers for the detection of micrometastatic breast cancer. Clinical Cancer Research, 11, 3697–704.

    Article  PubMed  CAS  Google Scholar 

  91. Muller, V., Stahmann, N., Riethdorf, S., Rau, T., Zabel, T., Goetz, A., et al. (2005). Circulating tumor cells in breast cancer: Correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clinical Cancer Research, 11, 3678–685.

    Article  PubMed  Google Scholar 

  92. Pantel, K., Muller, V., Auer, M., Nusser, N., Harbeck, N., & Braun, S. (2003). Detection and clinical implications of early systemic tumor cell dissemination in breast cancer. Clinical Cancer Research, 9, 6326–334.

    PubMed  CAS  Google Scholar 

  93. Gutman, F., Alberini, J., Lerebours, F., Gonthier, M., Wastski, M., Al Nakib, M., et al. (2005). 18-fluorodeoxyglucose positron emission tomography in initial diagnosis and staging of inflammatory breast tumors. Journal of Clinical Oncology, 25(Suppl 16), 51s. Abstract 691.

    Google Scholar 

  94. Frei, E. (1977). Rationale for combined therapy. Cancer, 40(Suppl 1), 569–73.

    Article  PubMed  Google Scholar 

  95. Danish Breast Cancer Cooperative Group, Nielsen, H. M., Overgaard, M., Grau, C., Jensen, A. R., & Overgaard, J. (2006). Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: Long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. Journal of Clinical Oncology, 24, 2268–275.

    Article  PubMed  Google Scholar 

  96. Veronesi, U., Cascinelli, N., Mariani, L., Greco, M., Saccozzi, R., Luini, A., et al. (2002). Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. New England Journal of Medicine, 347, 1227–232.

    Article  PubMed  Google Scholar 

  97. Rugo, H. S. (2007). Adjuvant therapies: Distant disease-free survival as a predictor of overall survival. St. Gallen Symposium; May 31’June 2, 2007; St Gallen, Switzerland, Abstract 120.

  98. Rutqvist, L. E., Cedermark, B., Glas, U., Johansson, H., Nordenskjold, B., Skoog, L., et al. (1987). The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Research Treatment, 10, 255–66.

    Article  CAS  Google Scholar 

  99. Ludwig Breast Cancer Study Group. (1984). Randomized trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet, 1, 1256–260.

    Google Scholar 

  100. Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., et al. (2005). Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer. Journal of Clinical Oncology, 23(16s), 6s, Abstract 510.

    Google Scholar 

  101. Loi, S., Piccart, M. J., Haibe-Kains, B., Desmedt, C., Harris, A. L., Bergh, J., et al. (2005). Prediction of early distant relapses on tamoxifen in early-stage breast cancer (BC): A potential tool for adjuvant aromatase inhibitor (AI) tailoring. Journal of Clinical Oncology, 23(Suppl 16), 6s, Abstract 509.

    Google Scholar 

  102. Howell, A., Cuzick, J., Baum, J., Buzdar, A., Dowsett, M., Forbes, J. F., et al. (2005). Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years–adjuvant treatment for breast cancer. Lancet, 365, 60–2.

    Article  PubMed  CAS  Google Scholar 

  103. Coombes, R. C., Paridaens, R., Jassem, J., et al, for the Intergroup Exemestane Study (IES). (2006). First mature analysis of the Intergroup Exemestane Study. Journal of Clinical Oncology, 24(Suppl 18), 933s, Abstract LBA527.

    Google Scholar 

  104. Mansell, J., Monypenny, I. J., Skene, A. I., Abram, P., Gattuso, J., Abdel-Rahman, A., et al. (2006). Predictors of early recurrence in postmenopausal women with operable breast cancer. Breast Cancer Research Treatment, 100(Suppl 1), S111, Abstract 2091.

    Google Scholar 

  105. Baum, M., Demicheli, R., Hrushesky, W., & Retsky, M. (2005). Does surgery unfavourably perturb the “natural history–of early breast cancer by accelerating the appearance of distant metastases? European Journal of Cancer, 41, 508–15.

    Article  PubMed  Google Scholar 

  106. Mauriac, L. (2006). Aromatase inhibitors: effective endocrine therapy in the early adjuvant setting for postmenopausal women with hormone-responsive breast cancer. Best Practice and Research, Clinical Endocrinology and Metabolism, 20(Suppl 1), S15’S29.

    Article  CAS  Google Scholar 

  107. Houghton, J. (2006). Initial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T)—data reported on behalf of the ATAC (‘Arimidex– tamoxifen, alone or in combination) Trialists–Group. Annals of Oncology, 17(Suppl 9), ix94, Abstract 243PD.

    Google Scholar 

  108. Leeming, D. J., Koizumi, M., Byrjalsenm, I., Li, B., Qvist, P., & Tanko, L. B. (2006). The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiology, Biomarkers & Prevention, 15, 32–8.

    Article  CAS  Google Scholar 

  109. Santini, D., Fratto, M. E., Vincenzi, B., Galluzzo, S., & Tonini, G. (2006). Zoledronic acid in the management of metastatic bone disease. Expert Opinion on Biological Therapy, 6, 1333–348.

    Article  PubMed  CAS  Google Scholar 

  110. Diel, I. J., Solomayer, E. F., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D., et al. (1998). Reduction in new metastases in breast cancer with adjuvant clodronate treatment. New England Journal of Medicine, 339, 357–63.

    Article  PubMed  CAS  Google Scholar 

  111. Saad, F. (2005). Zoledronic acid: Past, present and future roles in cancer treatment. Future Oncology, 1, 149–59.

    Article  PubMed  CAS  Google Scholar 

  112. Vincenzi, B., Santini, D., Dicuonzo, G., Battistoni, F., Gavasci, M., La Cesa, A., et al. (2005). Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. Journal of Interferon & Cytokine Research, 25, 144–51.

    Article  CAS  Google Scholar 

  113. Garnero, P., Buchs, N., Zekri, J., Rizzoli, R., Colemann, R. E., & Delmas, P. D. (2000). Markers of bone turnover for the management of patients with bone metastases from prostate cancer. British Journal of Cancer, 82, 858–64.

    Article  PubMed  CAS  Google Scholar 

  114. Demers, L. M., Costa, L., & Lipton, A. (2000). Biochemical markers and skeletal metastases. Cancer, 88, 2919–926.

    Article  PubMed  CAS  Google Scholar 

  115. Coleman, R. E., Major, P., Lipton, A., Brown, J. E., Lee, K.-A., Smith, M., et al. (2005). Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. Journal of Clinical Oncology, 23, 4925–935.

    Article  PubMed  CAS  Google Scholar 

  116. Clemons, M., Dranitsaris, G., Cole, D., & Gainford, M. C. (2006). Too much, too little, too late to start again? Assessing the efficacy of bisphosphonates in patients with bone metastases from breast cancer. Oncologist, 11, 227–33.

    Article  PubMed  CAS  Google Scholar 

  117. Sarto, T., Blomqvist, C., Virkkunen, P., & Elomaa, I. (2001). Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. Journal of Clinical Oncology, 19, 10–7.

    Google Scholar 

  118. Lipton, A. (2006). Future treatment of bone metastases. Clinical Cancer Research, 12, 6305s–308s.

    Article  PubMed  CAS  Google Scholar 

  119. Guarneri, V., Donati, S., Nicolini, M., Giovannelli, S., D’Amico, R., & Conte, P. F. (2005). Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist, 10, 842–48.

    Article  PubMed  CAS  Google Scholar 

  120. Khalili, P., Arakelian, A., Chen, G., Singh, G., Rabbani, S. A. (2006). Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer. Oncogene, 24, 6657–666.

    Article  CAS  Google Scholar 

  121. Romond, E. H., Perez, E. A., Bryant, J., et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine, 353, 1673–684.

    Article  PubMed  CAS  Google Scholar 

  122. McClung, M. R., Lewiecki, E. M., Cohen, S. B., et al., for the AMG 162 Bone Loss Study Group. (2006). Denosumab in postmenopausal women with low bone mineral density. New England Journal of Medicine, 354, 821–31.

    Article  PubMed  CAS  Google Scholar 

  123. Nilsson, S., Larsen, R. H., Fossa, S. D., Balteskard, L., Borch, K. W., Westlin, J.-E., et al. (2005). First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clinical Cancer Research, 11, 4451–459.

    Article  PubMed  CAS  Google Scholar 

  124. Goblirsch, M., Zwolak, P., Ramnaraine, M. L., Pan, W., Lynch, C., Alaei, P., et al. (2006). Novel cytosine deaminase fusion gene enhances the effect of radiation on breast cancer in bone by reducing tumor burden, osteolysis, and skeletal fracture. Clinical Cancer Research, 12, 3168–176.

    Article  PubMed  CAS  Google Scholar 

  125. Rahman, K. M., Sarkar, F. H., Banerjee, S., Wang, Z., Liao, D. J., Hong, X., et al. (2006). Therapeutic intervention of experimental breast cancer bone metastasis by indole-3-carbinol in SCID-human mouse model. Molecular Cancer Therapeutics, 5, 2747–756.

    Article  PubMed  CAS  Google Scholar 

  126. Bauerle, T., Peterschmitt, J., Hilbig, H., Kiessling, F., Armbruster, F. P., & Berger, M. R. (2006). Treatment of bone metastasis induced by MDA-MB-231 breast cancer cells with an antibody against bone sialoprotein. International Journal of Oncology, 28, 573–83.

    PubMed  Google Scholar 

  127. Khalili, P., Arakelian, A., Chen, G., Plunkett, M. L., Beck, I., Parry, G. C., et al. (2006). A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Molecular Cancer Therapeutics, 5, 2271–280.

    Article  PubMed  CAS  Google Scholar 

  128. Bandyopadhyay, A., Agyin, J. K., Wang, L., Tang, Y., Lei, Z., Story, B. M., et al. (2006). Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Research, 66, 6714–721.

    Article  PubMed  CAS  Google Scholar 

  129. Saito, H., Tsunenari, T., Onuma, E., Sato, K., Ogata, E., & Yamada-Okabe, H. (2005). Humanized monoclonal antibody against parathyroid hormone-related protein suppresses osteolytic bone metastasis of human breast cancer cells derived from MDA-MB-231. Anticancer Research, 25, 3817–823.

    PubMed  CAS  Google Scholar 

  130. Harms, J. F., Welch, D. R., Samant, R. S., et al. (2004). A small molecule antagonist of the αvβ3 integrin suppresses MDA-MB-435 skeletal metastasis. Clinical & Experimental Metastasis, 21, 119–28.

    Article  CAS  Google Scholar 

  131. El Abdaimi, K., Dion, N., Papavasiliou, V., Cardinal, P.-E., Binderup, L., Goltzman, D., et al. (2000). The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Research, 60, 4412–418.

    PubMed  Google Scholar 

  132. Whyte, M. P. (2006). The long and the short of bone therapy. New England Journal of Medicine, 354, 860–63.

    Article  PubMed  CAS  Google Scholar 

  133. Bellahcene, A., Bachelier, R., Detry, C., Lidereau, R., Clezardin, P., & Castronovo, V. (2007). Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Research Treatment, 10, 135–48.

    Google Scholar 

  134. Bendre, M. S., Marguliesm, A. G., Walser, B., Akel, N. S., Bhattacharrya, S., Skinner, R. A., et al. (2005). Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-κB ligand pathway. Cancer Research, 65, 11001–1009.

    Article  PubMed  CAS  Google Scholar 

  135. Shimo, T., Kubota, S., Yoshioka, N., Ibaragi, S., Isowa, S., Eguchi, T., et al. (2006). Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. Journal of Bone and Mineral Research, 21, 1045–059.

    Article  PubMed  CAS  Google Scholar 

  136. Yi, B., Williams, P. J., Niewolna, M., Wang, Y., & Yoneda, T. (2002). Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Research, 62, 917–23.

    PubMed  CAS  Google Scholar 

  137. Park, B. K., Zhang, H., Zeng, Q., Dai, J., Keller, E. T., Giordano, T., et al. (2007). NF-κB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nature Medicine, 13, 62–9.

    Article  PubMed  CAS  Google Scholar 

  138. Bellahcene, A., & Castronovo, V. (1995). Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. American Journal of Pathology, 146, 95–00.

    PubMed  CAS  Google Scholar 

  139. Bellahcene, A., Kroll, M., Liebens, F., & Castronovo, V. (1996). Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. Journal of Bone and Mineral Research, 11, 665–70.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, McGill University Health Centre, Montreal, QC, Canada

    Shafaat A. Rabbani

  2. Attenuon, LLC, San Diego, CA, USA

    Andrew P. Mazar

Authors
  1. Shafaat A. Rabbani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew P. Mazar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shafaat A. Rabbani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rabbani, S.A., Mazar, A.P. Evaluating distant metastases in breast cancer: from biology to outcomes. Cancer Metastasis Rev 26, 663–674 (2007). https://doi.org/10.1007/s10555-007-9085-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10555-007-9085-8

Keywords

Search

Navigation